Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

        Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC

Amezalpat builds momentum with both Fast Track and Orphan Drug Designations

Read more at globenewswire.com